<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809285</url>
  </required_header>
  <id_info>
    <org_study_id>CIP331</org_study_id>
    <nct_id>NCT04809285</nct_id>
  </id_info>
  <brief_title>Use of the Guardian™ Connect System With Smart Connected Devices</brief_title>
  <official_title>Use of the Guardian™ Connect System With Smart Connected Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data&#xD;
      for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device&#xD;
      wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking&#xD;
      and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, prospective single-arm design without controls. All subjects&#xD;
      will participate for a minimum of 90 days (Phase 1) and some subjects 18 years of age or&#xD;
      older will participate for up to 9 months (Phase 2). All subjects will wear the Guardian&#xD;
      Connect system (real-time continuous glucose monitoring (CGM)) continuously and use smart&#xD;
      insulin pens or insulin pens with smart caps for multiple daily injections and continue their&#xD;
      standard therapy throughout the duration of the study.&#xD;
&#xD;
      The subject's insulin delivery, sleep, physical activity (as applicable), food intake data,&#xD;
      and medication (as applicable) will be collected through applications with meal logging and&#xD;
      medication requiring manual entry. In addition, subjects may also participate in optional&#xD;
      self-administered insulin injection video capture and upload using a secure cloud-based site&#xD;
      and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using&#xD;
      BodyGuardian MINI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Time in Range</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Percentage of Time in Range (SG &lt;70 mg/dL, 70-180 mg/dL, and &gt;180 mg/dL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Guardian™ Connect system, InPen™ Basal smart cap, and smart insulin pens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will wear the Guardian Connect system (real-time continuous glucose monitoring (CGM)) continuously and use smart insulin pens or insulin pens with smart caps for multiple daily injections and continue their standard therapy throughout the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app</intervention_name>
    <description>Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.</description>
    <arm_group_label>Guardian™ Connect system, InPen™ Basal smart cap, and smart insulin pens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Individual is 2-80 years of age at time of consent.&#xD;
&#xD;
          2. A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator for:&#xD;
&#xD;
               -  at least the last 6 months for subjects 2-6 years of age&#xD;
&#xD;
               -  at least the last 12 months for subjects 7-80 years of age&#xD;
&#xD;
          3. Subject is on multiple daily injection therapy (3 or more insulin injections per day&#xD;
             one of which is a long acting insulin injection), is currently using or is willing and&#xD;
             can afford to use insulin pen(s) and pen cartridge(s).&#xD;
&#xD;
          4. Subject is currently using or is willing to use the Guardian Connect system during the&#xD;
             study.&#xD;
&#xD;
          5. Subject agrees to comply with the study protocol requirements.&#xD;
&#xD;
          6. For adult subjects: Subject is capable of providing legal consent without a legal&#xD;
             authorized representative.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subject is using a syringe and unwilling or unable to use insulin pen(s).&#xD;
&#xD;
          2. Subject is using an insulin pump.&#xD;
&#xD;
          3. Subject is currently using a non-Medtronic standalone CGM system and unwilling to use&#xD;
             only the Guardian Connect system during the study.&#xD;
&#xD;
          4. Subject is using hydroxyurea at time of screening or plans to use it during the study.&#xD;
&#xD;
          5. Subject will not tolerate tape adhesive in the area of device placement as assessed by&#xD;
             a qualified provider.&#xD;
&#xD;
          6. Subject has any unresolved adverse skin condition in the area of device placement&#xD;
             (e.g. psoriasis, rash, Staphylococcus infection).&#xD;
&#xD;
          7. Subject is actively participating in or plans to enroll in an investigational study&#xD;
             (e.g. drug or device), other than this study, wherein they have received treatment&#xD;
             from an investigational drug or device.&#xD;
&#xD;
          8. Subject has a positive urine pregnancy test at time of screening.&#xD;
&#xD;
          9. Subject is female, sexually active without the use of contraception, able to become&#xD;
             pregnant or plans to become pregnant during the course of the study.&#xD;
&#xD;
         10. Subject is unwilling to participate in study procedures.&#xD;
&#xD;
         11. Subject is directly involved in the study as research staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eileen Sneeden</last_name>
    <phone>818-576-5203</phone>
    <email>eileen.sneeden@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Diabetes and Endocrinology Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spencer Francis</last_name>
      <phone>501-850-8285</phone>
      <email>spenf@medvestinc.com</email>
    </contact>
    <investigator>
      <last_name>James Thrasher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354-3811</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Jacobson</last_name>
      <phone>909-558-3022</phone>
      <email>cjacobson@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Codorniz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salinas Valley Memorial Healthcare System</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901-4483</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Morales</last_name>
      <phone>831-759-3051</phone>
      <email>jmorales3@svmh.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas Kissell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Fivekiller</last_name>
      <phone>303-724-8977</phone>
      <email>emily.fivekiller@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Slover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizzie Huckaby</last_name>
      <phone>404-355-4393</phone>
      <email>LHuckaby@atlantadiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Bode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Tapia</last_name>
      <phone>678-878-4750</phone>
      <email>jtapia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Reed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Draffin</last_name>
      <phone>901-384-0065</phone>
      <email>ldraffin@amdiabetes.net</email>
    </contact>
    <investigator>
      <last_name>Kashif Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Lopez</last_name>
      <phone>512-334-3505</phone>
      <phone_ext>3</phone_ext>
      <email>elopez@texasdiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Lindsay Harrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Montoya</last_name>
      <phone>512-334-3505</phone>
      <phone_ext>2</phone_ext>
      <email>dmontoya@texasdiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Luis Casaubon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainer Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Aaker</last_name>
      <phone>425-251-1720</phone>
      <email>laaker@rainier-research.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Brazg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

